GlassScriptPhysician profile
Gregory A Moffitt
NPI 1962403675
$4,599.58
in general payments reported to CMS, 2019-2025
30 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $580 · 2021: $208 · 2022: $1,024 · 2023: $791 · 2024: $456 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,150.00 | 2019-2020 | |
| Novo Nordisk INC | $622.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $484.20 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $389.27 | 2019-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $237.21 | 2019-2025 | Jardiance |
| Amgen INC. | $198.68 | 2019-2025 | Tepezza, Repatha |
| Novartis Pharmaceuticals Corporation | $186.41 | 2022-2023 | |
| Horizon Therapeutics Plc | $178.22 | 2019-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $159.16 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $123.27 | 2019-2024 | Omnipod |
| Mannkind Corporation | $121.79 | 2022-2023 | Afrezza |
| Corcept Therapeutics | $93.47 | 2020-2025 | Korlym |
| Pfizer INC. | $76.99 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $75.09 | 2025 | Yorvipath |
| Nevro Corp. | $67.28 | 2021-2023 | Senza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57.52 | 2021-2023 | |
| Senseonics, Incorporated | $45.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.83 | 2019-2024 | |
| Lifescan, INC. | $41.31 | 2019 | |
| Radius Health, INC. | $40.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.06 | 2022 | |
| Gilead Sciences, INC. | $34.22 | 2019 | |
| Cequr Corporation | $29.60 | 2024-2025 | Cequr Simplicity |
| Medtronic, INC. | $21.31 | 2024 | Intellis Adaptivestim |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.24 | 2024 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $15.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2021 | |
| Companion Medical, INC. | $12.86 | 2020 | |
| Esperion Therapeutics, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Moffitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.